Single nucleotide polymorphisms in angiogenesis-related genes and outcomes from antiangiogenic therapies in renal cell carcinoma: really a step towards personalized oncology, or not at all?
作者信息
Porta Camillo, Cosmai Laura, Rizzo Mimma, Melazzini Mario
机构信息
Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy.
Division of Translational Oncology, I.R.C.C.S. Istituti Clinici Scientifici Maugeri, Pavia, Italy.
出版信息
Ann Transl Med. 2019 Mar;7(Suppl 1):S15. doi: 10.21037/atm.2019.01.51.
Abstract
摘要
相似文献
1
Single nucleotide polymorphisms in angiogenesis-related genes and outcomes from antiangiogenic therapies in renal cell carcinoma: really a step towards personalized oncology, or not at all?血管生成相关基因中的单核苷酸多态性与肾细胞癌抗血管生成治疗的结果：这真的是迈向个性化肿瘤学的一步，还是并非如此？
Ann Transl Med. 2019 Mar;7(Suppl 1):S15. doi: 10.21037/atm.2019.01.51.
2
Single nucleotide polymorphisms as prognostic and predictive biomarkers in renal cell carcinoma.单核苷酸多态性作为肾细胞癌的预后和预测生物标志物
Oncotarget. 2017 Nov 20;8(63):106551-106564. doi: 10.18632/oncotarget.22533. eCollection 2017 Dec 5.
3
Pharmacogenomic biomarkers for personalized cancer treatment.用于癌症个体化治疗的药物基因组生物标志物。
J Intern Med. 2015 Feb;277(2):201-217. doi: 10.1111/joim.12321.
4
Renal carcinoma pharmacogenomics and predictors of response: Steps toward treatment individualization.肾癌的药物基因组学与反应预测因子：迈向个体化治疗的步骤
Urol Oncol. 2015 Apr;33(4):179-86. doi: 10.1016/j.urolonc.2013.09.015. Epub 2014 Feb 1.
5
Antiangiogenic drugs for colorectal cancer: exploring new possibilities.结直肠癌的抗血管生成药物：探索新的可能性。
Clin Colorectal Cancer. 2013 Mar;12(1):1-7. doi: 10.1016/j.clcc.2012.06.002. Epub 2012 Jul 3.
6
Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations?肿瘤学中抗血管生成疗法发展的血管生成生物标志物：工具还是装饰？
Nat Clin Pract Oncol. 2008 Jul;5(7):378-91. doi: 10.1038/ncponc1150. Epub 2008 Jun 17.
7
8
Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy.舒尼替尼或索拉非尼对接受过先前抗血管生成治疗的转移性肾细胞癌患者的抗肿瘤作用。
J Urol. 2008 Jan;179(1):81-6; discussion 86. doi: 10.1016/j.juro.2007.08.127. Epub 2007 Nov 12.
10
Impact of polymorphisms in angiogenesis-related genes on clinical outcomes of radiotherapy in patients with nasopharyngeal carcinoma.
Clin Exp Pharmacol Physiol. 2017 May;44(5):539-548. doi: 10.1111/1440-1681.12738.
引用本文的文献
1
The optimal timing and courses of bevacizumab added to chemotherapy for non-squamous non-small cell lung cancer: revelations from the real-world experience in a single Chinese cancer center.贝伐单抗联合化疗用于非鳞状非小细胞肺癌的最佳时机和疗程：来自中国一家癌症中心真实世界经验的启示
Ann Transl Med. 2020 Oct;8(20):1311. doi: 10.21037/atm-20-6327.
本文引用的文献
1
Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis.辅助舒尼替尼治疗高危肾细胞癌的 III 期临床试验：探索性药物基因组学分析。
Clin Cancer Res. 2019 Feb 15;25(4):1165-1173. doi: 10.1158/1078-0432.CCR-18-1724. Epub 2018 Nov 6.
2
The search for gene-gene interactions in genome-wide association studies: challenges in abundance of methods, practical considerations, and biological interpretation.全基因组关联研究中基因-基因相互作用的探索：方法众多带来的挑战、实际考量及生物学解释
Ann Transl Med. 2018 Apr;6(8):157. doi: 10.21037/atm.2018.04.05.
3
Biomarker-guided antibiotic therapy-strengths and limitations.生物标志物引导的抗生素治疗——优势与局限
Ann Transl Med. 2017 May;5(10):208. doi: 10.21037/atm.2017.04.04.
4
Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib-Treated Cancer.在接受舒尼替尼治疗的癌症患者中，整合药代动力学、药效学、药物遗传学和临床结局的群体建模。
CPT Pharmacometrics Syst Pharmacol. 2017 Sep;6(9):604-613. doi: 10.1002/psp4.12210. Epub 2017 Jul 13.
5
Limits to Precision Cancer Medicine.精准癌症医学的局限性
N Engl J Med. 2017 Jan 5;376(1):96-7. doi: 10.1056/NEJMc1613563.
6
Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.辅助舒尼替尼治疗肾切除术后高危肾细胞癌。
N Engl J Med. 2016 Dec 8;375(23):2246-2254. doi: 10.1056/NEJMoa1611406. Epub 2016 Oct 9.
7
Evaluation of polymorphisms in angiogenesis-related genes as predictive and prognostic markers for sunitinib-treated metastatic renal cell carcinoma patients.评估血管生成相关基因多态性作为舒尼替尼治疗转移性肾细胞癌患者的预测和预后标志物。
J Cancer Res Clin Oncol. 2016 Jun;142(6):1171-82. doi: 10.1007/s00432-016-2137-0. Epub 2016 Mar 3.
8
Kidney cancer: Single nucleotide polymorphisms in mRCC-is their time up?肾癌：转移性肾细胞癌中的单核苷酸多态性——它们的时代结束了吗？
Nat Rev Urol. 2015 Aug;12(8):424-6. doi: 10.1038/nrurol.2015.149. Epub 2015 Jun 30.
9
CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.CYP3A5 和 ABCB1 多态性作为转移性肾细胞癌舒尼替尼疗效的预测因子。
Eur Urol. 2015 Oct;68(4):621-9. doi: 10.1016/j.eururo.2015.04.018. Epub 2015 Apr 27.
10
Technical reproducibility of single-nucleotide and size-based DNA biomarker assessment using DNA extracted from formalin-fixed, paraffin-embedded tissues.使用从福尔马林固定、石蜡包埋组织中提取的DNA进行单核苷酸和基于大小的DNA生物标志物评估的技术可重复性。
J Mol Diagn. 2015 May;17(3):242-50. doi: 10.1016/j.jmoldx.2014.12.001. Epub 2015 Mar 4.
Zotero 插件